AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11386491
Drug: naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone 50 mg/day with cognitive coping skills
Trial: 9243422
Drug: Physical fitness
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical fitness program as an adjunct to the usual program
Trial: 9243422
Drug: Physical fitness
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical fitness program with therapy
Trial: 8474059
Drug: Gold therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold therapy (early treatment)
Trial: 8474059
Drug: Delayed gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed gold therapy (treatment after 6 months)
Trial: 31600221
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene Blue (MB) with Artesunate-Amodiaquine (AS-AQ) (15 mg/kg/day for 3 days)
Trial: 31600221
Drug: Primaquine (PQ)
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine (PQ) with Artesunate-Amodiaquine (AS-AQ) (0.25 mg/kg at day 2)
Trial: 28178004
Drug: Combined Jessner
RxNorm normalized name: lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Jessner solution and TCA (20%-25%)
Trial: 21865364
Drug: Atropine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (15 μg/kg bolus, 4 μg/kg · h infusion)
Trial: 21865364
Drug: Physostigmine (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (0.12 μg/kg · min)
Trial: 17109305
Drug: Buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone treatment with brief physician management
Trial: 17109305
Drug: Buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone treatment with physician management and nurse-administered drug counseling
Trial: 9578185
Drug: Imidapril 10
RxNorm normalized name: imidapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril 10 mg single dose
Trial: 9578185
Drug: Imidapril 10
RxNorm normalized name: imidapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril 10 mg steady state (28 days therapy)
Trial: 1282183
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg nitroglycerin
Trial: 31788775
Drug: Lateral position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral position (L)
Trial: 31451978
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) with therapist support
Trial: 31451978
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) without therapist support
Trial: 25876640
Drug: Sufentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil group (S) - 150 mL normal saline containing 2.5 µg/kg sufentanil citrate and 6 mg tropisetron for 48 hours
Trial: 25876640
Drug: Dezocine+sufentanil group
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dezocine+sufentanil group (DS) - 150 mL normal saline containing 0.25 mg/kg dezocine, 1.5 µg/kg sufentanil citrate, and 6 mg tropisetron for 48 hours
Trial: 21103921
Drug: Lycopene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene (30 mg/day)
Trial: 21103921
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (3 g/day, including 1,098 mg eicosapentaenoic and 549 mg docosahexaenoic fatty acids)
Trial: 31615937
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Abemaciclib + Anastrozole)
Trial: 31615937
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Abemaciclib, Anastrozole, Combination)
Trial: 27113948
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA (1.95g orally 2 hours preoperatively)
Trial: 24690201
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment (clinician controlled), receiving care on a regular basis
Trial: 24690201
Drug: Symptom-guided treatment
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-guided treatment (patient controlled), receiving care when patients feel a need
Trial: 24690201
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment (clinician controlled)
Trial: 24690201
Drug: Symptom-guided treatment
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-guided treatment (patient controlled)
Trial: 18607963
Drug: Intratympanic gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic gentamicin treatment
Trial: 16322468
Drug: Total therapy
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total therapy 2 without thalidomide (TT2)
Trial: 12936973
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg single oral dose
Trial: 21499876
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment programs (control group)
Trial: 20007923
Drug: BIBW 2948
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2948 (15 mg twice a day)
Trial: 20007923
Drug: BIBW 2948
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2948 (30 mg twice a day)
Trial: 18673350
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and diphenhydramine
Trial: 15910627
Drug: Insulin-treated Type
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated Type 2 diabetes
Trial: 12632426
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin plus low-dose aspirin
Trial: 8785254
Drug: Rifabutin in
RxNorm normalized name: Product containing rifabutin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin in combination with isoniazid, ethambutol, and clofazimine
Trial: 1718367
Drug: Zinc supplements
RxNorm normalized name: Zinc Supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplements (30 mg/d for 3 d)
Trial: 22978561
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First intervention (Assertive Community Treatment for high needs participants and Intensive Case Management for moderate needs participants)
Trial: 18031315
Drug: Pioglitazone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (7.5 mg/day) added to flutamide (62.5 mg/day) and metformin (850 mg/day)
Trial: 15919695
Drug: Daily haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily haemodialysis (DHD) - 2-3 hours, 6 times/week
Trial: 11471639
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of etodolac
Trial: 9094887
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acid (PUFA) ingestion (low dosage)
Trial: 9094887
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acid (PUFA) ingestion (high dosage)
Trial: 8104091
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg IV bolus of etilefrine followed by continuous infusion (0.35 mg.kg‐1.h‐1)
Trial: 8104091
Drug: 30 ml.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml.kg‐1 infusion of saline isotonic solution for 90 min
Trial: 8104091
Drug: No preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preventive treatment (control group)
Trial: 2883784
Drug: DTP vaccine,
RxNorm normalized name: DTP Vaccine, intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine, initial immunization at five months of age or later, second dose at eight weeks or more
Trial: 2883784
Drug: DTP vaccine,
RxNorm normalized name: DTP Vaccine, intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine, initial immunization at ages less than five months
Trial: 24630820
Drug: Burn rehabilitation
RxNorm normalized name: Burn Jel Plus
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Burn rehabilitation massage therapy
Trial: 24630820
Drug: Standard rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rehabilitation therapy for hypertrophic scars
Trial: 22471132
Drug: Tolterodine 1
RxNorm normalized name: tolterodine 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 1 mg orally, twice a day + electroacupuncture (Baihui, Sishengcong, Yintang) once a day
Trial: 22471132
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg orally, twice a day
Trial: 19825835
Drug: Evening administered
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administered bimatoprost/timolol fixed combination (BTFC)
Trial: 19825835
Drug: Morning administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administered bimatoprost/timolol fixed combination (BTFC)
Trial: 27272076
Drug: Bimatoprost monotherapy
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost monotherapy
Trial: 15692986
Drug: Meloxicam 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 0.125 mg/kg body weight (single daily dose)
Trial: 15692986
Drug: Meloxicam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 0.25 mg/kg body weight (single daily dose)
Trial: 15692986
Drug: Naproxen 10
RxNorm normalized name: naproxen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 10 mg/kg body weight (2 daily doses)
Trial: 12685513
Drug: Nicardipine 60
RxNorm normalized name: niCARdipine 60 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 60 mg/day (titrated to 10 mg/day if necessary)
Trial: 10327211
Drug: Cellular and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellular and cytokine therapy
Trial: 7720349
Drug: Five small
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five small hourly meals
Trial: 7188111
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg X 3/day/4 weeks p.o.)
Trial: 31472669
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 60 mg.kg-1
Trial: 22305829
Drug: TAXUS Liberté
RxNorm normalized name: Taxus baccata fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAXUS Liberté stent with concomitant prasugrel therapy (1 year)
Trial: 22305829
Drug: Prasugrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel plus aspirin (1 year)
Trial: 22305829
Drug: Prasugrel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (5 and 10 mg daily doses)
Trial: 22305829
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (12 versus 30 months)
Trial: 21163755
Drug: DD-I (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DD-I (patients before treatment)
Trial: 21163755
Drug: DD-II (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DD-II (patients after 8 weeks of pharmacological treatment)
Trial: 16319260
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron polymaltose complex (300 mg elemental iron per day)
Trial: 12411535
Drug: Antioxidants (AOX)
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (AOX) ascorbic acid (2 g, I.V.) and alpha‐tocopherol (200 mg, P.O.)
Trial: 10445218
Drug: Iron plus
RxNorm normalized name: Nu-Iron Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron plus zinc supplementation (12 mg/day of Fe+++ and 12.5 mg/day of Zn++)
Trial: 10445218
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (12.5 mg/day of Zn++)
Trial: 8575690
Drug: Vagifem (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagifem (25 micrograms oestradiol) administered as vaginal pessaries daily, 3 weeks prior to surgery
Trial: 8575690
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as vaginal pessaries daily, 3 weeks prior to surgery
Trial: 8575690
Drug: Preoperative oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative oestradiol treatment
Trial: 8575690
Drug: Preoperative placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative placebo treatment
Trial: 2427144
Drug: Terfenadine (H1-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (H1-receptor antagonist)
Trial: 24865945
Drug: Auricular acupressure
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupressure (AA) treatment for 8 weeks
Trial: 19358184
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (intravenous for 24 hours, followed by oral for 10 days)
Trial: 12088166
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment
Trial: 12088166
Drug: Acute and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute and maintenance treatment
Trial: 8187941
Drug: azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Trial: 8187941
Drug: cetirizine tablets
RxNorm normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cetirizine tablets 10 mg once daily
Trial: 8187941
Drug: azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azelastine nasal spray
Trial: 27849166
Drug: FR104 (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FR104 (0.02 mg/kg to 1.500 mg/kg)
Trial: 22726372
Drug: D-dimer levels
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer levels <500 μg/l
Trial: 21098580
Drug: Daily remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily remote device monitoring (electrocardiogram, blood pressure, body weight) coupled with medical telephone support
Trial: 21098580
Drug: Daily remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily remote device monitoring
Trial: 16351673
Drug: Single steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single steroid injection (methylprednisolone acetate) plus saline injection at 8 weeks
Trial: 16351673
Drug: Double steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double steroid injections (methylprednisolone acetate) at baseline and at 8 weeks
Trial: 16351673
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (single and double injections)
Trial: 7034861
Drug: Autogenous wart
RxNorm normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenous wart vaccine
Trial: 28356068
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (deflated cuff)
Trial: 17437877
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (treatment solution with subsequent NaOCl application)
Trial: 17437877
Drug: Single treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatments
Trial: 17437877
Drug: Treatment time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment time of 5 minutes
Trial: 11506819
Drug: Quercetin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (30 mg per day)
Trial: 2538094
Drug: Bupivacaine dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine dosage during first stage of labor
Trial: 21995590
Drug: NOMAC/E2 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen
Trial: 21995590
Drug: DRSP/EE (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRSP/EE (3 mg/30 μg) in a 21/7-day regimen
Trial: 25066875
Drug: Prostate capsule
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate capsule sparing cystectomy
Trial: 21980799
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a high-dose 6-grass pollen preparation
Trial: 17924020
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group, n=210, 354 teeth)
Trial: 10702458
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (100 microg. kg(‐1). min(‐1))
Trial: 8922197
Drug: Sequential biochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential biochemotherapy (CVD followed by IL-2 and IFN-alpha)
Trial: 2861876
Drug: Sulphasalazine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine 1.5 g/day
Trial: 2861876
Drug: Sulphasalazine 3
RxNorm normalized name: sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine 3 g/day
Trial: 2861876
Drug: Sulphasalazine >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine > 40 mg/kg/day
Trial: 30292919
Drug: Skin tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin tests (prick and intradermal tests) for taxanes
Trial: 26009799
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT; 100 μg) introduced in a single dose after three hours from the beginning of TK analgesia (TKF treatment)
Trial: 26009799
Drug: Ketorolac (0.86
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (0.86 mg/kg/day) and tramadol (7.2 mg/kg/day) (TK treatment)
Trial: 26009799
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT; 100 μg)
Trial: 22672794
Drug: I-ONE therapy
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-ONE therapy (PEMFs) for 4 hours/day for 60 days
Trial: 22672794
Drug: I-ONE therapy
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-ONE therapy (PEMFs)
Trial: 15013307
Drug: MM-Cept 500
RxNorm normalized name: IV PREP KIT (CEPTI-SEAL) #26-48-53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MM-Cept 500 mg tablets
Trial: 15013307
Drug: Cellcept 500
RxNorm normalized name: Cellcept 500mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellcept 500 mg tablets
Trial: 1873002
Drug: 12 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g/day SF
Trial: 1873002
Drug: 24 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g/day SF
Trial: 1873002
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day SF
Trial: 1873002
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three SF doses
Trial: 1873002
Drug: Seaweed preparation
RxNorm normalized name: seaweed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seaweed preparation
Trial: 6126067
Drug: Estazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam (1 + 1 + 4 mg)
Trial: 31897941
Drug: Cerebrolysin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (50 ml per day for 10 days, followed by two additional treatment cycles with 10 ml per day for 10 days)
Trial: 31223399
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (placebo)
Trial: 29551172
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (50 mg capsules, three times daily for 14 days)
Trial: 29551172
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (three times daily for 14 days)